hotspot -WSS

hotspot

author：fashion 2025-10-02 17:26:59 - browse：8635

An light blue number 3 with an eye is surrounded by smaller, black number 3s on an orange background — 3 to watch coverage from STAT — Christine Kao/STAT

It’s been a slow year for medtech. Major deals in 2023 were scarce, funding was hard to come by, and valuations were down. On the policy side, the industry grappled with changing AI regulations, reimbursement woes, and device sterilization rules.

Here are three political and market forces that shaped the medtech industry last year, and are worth paying attention to in 2024:

Lobbying power of AI, software-enabled devices

Medtech lobby AdvaMed announced earlier this month that the major medical imaging companies, previously housed within the National Electrical Manufacturers Association, were shifting to their shop. The device group also created a separate niche for digital health companies in October.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： Questions loom on AstraZeneca cancer drug as safety concerns ebb

explore

WSS

Medicare Advantage enrollment grows 7.1% to 33.4 million people

Elevance, SCAN deals highlight health insurer acquisition scrutiny

J&J lung cancer data amount to new salvo against AstraZeneca

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

ADCs take center stage as promising cancer treatments

hotspot

hotspot

Lobbying power of AI, software-enabled devices

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

UnitedHealth, Optum discontinue NaviHealth name

Tori Bowie and the unacceptable rates of Black maternal death

Obamacare plans could cover weight loss drugs

DIEP, the 'gold standard' of breast reconstruction, is under threat

Results on Novartis prostate cancer therapy could expand its use

Duchenne breakthrough therapy leaves behind pioneering families

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Novavax promises a turnaround & Lilly roils the obesity market

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

focus

Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

CZI to create biohub to build anti

Opioid cravings were reduced by anti

STAT Summit: Meghan O’Rourke on making chronic illness visible

As AI regulations shape up, health tech startups beg for clarity

Elevance, SCAN deals highlight health insurer acquisition scrutiny

explore

hotspot

explore

leisure time